These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3365590)

  • 1. [Peroperative disclosure of a case of malignant hyperthermia. Elements of suspicion of the diagnosis, in vitro study of the sensitivity of muscle fibers].
    Brasdefer D; Cantineau D; Tassin M; Krivosic-Horber R; Scherpereel P
    Cah Anesthesiol; 1988; 36(2):149-51. PubMed ID: 3365590
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia.
    Tollefson G
    J Clin Psychopharmacol; 1982 Aug; 2(4):266-70. PubMed ID: 6126494
    [No Abstract]   [Full Text] [Related]  

  • 3. Halothane-caffeine contracture testing in neuromuscular diseases.
    Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
    Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro caffeine test on skeletal muscle samples from swine].
    Rösel U; Szentkuti L
    Dtsch Tierarztl Wochenschr; 1993 Jan; 100(1):25-8. PubMed ID: 8428567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia.
    Christiaens F; Gepts E; D'Haese J; Camu F
    Acta Anaesthesiol Belg; 1995; 46(2):93-7. PubMed ID: 8714856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current data on the screening of malignant hyperthermia during anesthesia].
    Krivosic-Horber R; Adnet P
    Chirurgie; 1993-1994; 119(1-2):55-8. PubMed ID: 7995103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
    Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
    Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Malignant hyperthermia: difficulty in diagnosing susceptibility in Spain].
    Montes A; Ramos R; Trillo L; Silva T; Puig MM
    Rev Esp Anestesiol Reanim; 1999 Mar; 46(3):130-2. PubMed ID: 10228380
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro contracture tests for susceptibility to malignant hyperthermia.
    Rosenberg H; Reed S
    Anesth Analg; 1983 Apr; 62(4):415-20. PubMed ID: 6829945
    [No Abstract]   [Full Text] [Related]  

  • 11. Intraoperative hyperthermia in a child with neuroblastoma.
    Mayhew JF
    Paediatr Anaesth; 2006 Aug; 16(8):890-1. PubMed ID: 16884475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia and related neuromuscular diseases: caffeine contracture of the skinned muscle fibers.
    Takagi A; Sunohara N; Ishihara T; Nonaka I; Sugita H
    Muscle Nerve; 1983 Sep; 6(7):510-4. PubMed ID: 6633564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for malignant hyperthermia susceptibility.
    Anderson IL; Rawstron RE; Dunlop DJ
    N Z Med J; 1980 Jun; 91(661):417-9. PubMed ID: 6930029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of susceptibility to malignant hyperthermia in man.
    Ording H
    Br J Anaesth; 1988 Feb; 60(3):287-302. PubMed ID: 3279989
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility?
    Flewellen EH; Nelson TE
    Anesth Analg; 1984 Jul; 63(7):693-7. PubMed ID: 6731899
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of susceptibility to malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1974 May; 2(5913):245-7. PubMed ID: 4827071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulminant malignant hyperthermia.
    Bross T; Steinmann D
    Acta Anaesthesiol Scand; 2008 Jan; 52(1):164-5. PubMed ID: 18173438
    [No Abstract]   [Full Text] [Related]  

  • 19. Malignant hyperthermia in China.
    Xu ZH; Luo AL; Guo XY; Ren HZ; Wang YL; Zhang X; Huang YG; Ye TH
    Anesth Analg; 2006 Oct; 103(4):983-5. PubMed ID: 17000816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
    Britt BA; Scott EA
    Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.